Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer

International Journal of Clinical Pharmacy

Volumn 36, Issue 3, 2014, Pages 476-487

  Pérez Moreno, Maria Antonia ^a   Galván Banqueri, Mercedes ^a   Flores Moreno, Sandra ^a   Villalba Moreno, Ángela ^a   Cotrina Luque, Jesús ^a   Bautista Paloma, Francisco Javier ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Cancer; Efficacy; Non small cell lung cancer; Pemetrexed; Safety; Systematic review

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; PEMETREXED; PLACEBO; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADVERSE OUTCOME; ALTERNATIVE MEDICINE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; NEUTROPENIA; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; COST BENEFIT ANALYSIS; ECONOMICS; LUNG NEOPLASMS; SPAIN;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPAIN;

EID: 84901435129     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-014-9920-2     Document Type: Review

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Spanish Group of Lung Cancer. http://www.gecp.org/. Accessed 29 Oct 2013.
3. Hawes SE, Stern JE, Feng Q, Wiens LW, Rasey JS, Lu H, et al. DNA hypermethylation of tumors from non-small-cell (NSCLC) is associated with gender and histologic type. Lung Cancer. 2010;69:172-9.
4. Gorlova OY, Weng SF, Hernandez L, Spitz MR, Forman MR. Dietary patterns affect lung cancer risk in never smokers. Nutr Cancer. 2011;63:842-9.
5. De Matteis S, Consonni D, Lubin JH, Tucker M, Peters S, Vermeulen R, et al. Impact of occupational carcinogens on lung cancer risk in a general population. Int J Epidemiol. 2012;41:711-21.
6. Peng WJ, He Q, Yang JX, Wang BX, Lu MM, Wang S, et al. Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk. Mol Biol Rep. 2012;39:5187-94.
7. Villanueva-Herraiz S, Ortega-García MP, Camps-Herrero C, Blasco-Segura P. Study of use of pemetrexed in non-small cell lung cancer. Farm Hosp. 2010;34:194-203.
8. American Cancer Society Guidance on Lung Cancer Screening 2001.
9. Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep. 2004;11:559-95.
10. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy A pathophysiologic approach, vol 132. 8th ed. 2011. p. 2157-2173.
11. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology - small cell lung cancer. 2010. www.nccn.org/professionals/ physician-gls/default.asp. Accessed 29 Oct 2013.
12. Summary of product Characteristics. European medicines agency. http://www.ema.europa.eu/ema/. Accessed 29 Oct 2013.
13. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-51.
14. Novelló S, Pimentel FL, Douillard JY, O'Brien M, von Pawel H, Eckardt J, et al. Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cis-platin in chemonaïve patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5:1602-8.
15. Grønberg BH, Bremnes RM, Fløtten O, Amuelasen T, Brunsvig PF, Hjelde HH, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:3217-24.
16. Socinski MA, Raju RN, Stinchcombe T, Kocs DM, Couch LS, Barrera D, et al. Randomized phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol. 2010;5:1963-9.
17. Rodriguez-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, Ganju V, et al. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011;6:1907-14.
18. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet Oncol. 2009;374:1432-40.
19. Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, et al. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol. 2012;13:292-9.
20. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13:247-55.
21. Hanna N, Shepherd FA, Fossella FV, Rodrigues-Pereira J, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-97. (Pubitemid 41079796)
22. Al-Saleh K, Quinton C, Ellis PM. Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis. Curr Oncol. 2012;19:9-15.
23. Agulló-Ortuño MT, López-Ríos F, Paz-Ares L. Lung cancer genomic signatures. J Thorac Oncol. 2010;5:1673-91.
24. National Institute for Health and Clinical Excellence. Pemetrexed for the first-line treatment of non-small-cell lung cancer. NICE TA 181. 2009a. http://guidance.nice.org.uk/TA181. Accessed 29 Oct 2013.
25. Scagliotti GV, Par KK, Patil S, Rolski J, Goksel T, Martins R, et al. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. Eur J Cancer. 2009;45:2298-303.
26. Li M, Zhang Q, Fu P, Li P, Peng A, Zhang G, et al. Pemetrexed plus platinum as the first-line treatment option for evinced non-small cell lung cancer: a meta-analysis of randomized controlled trials. PLoS One. 2012;7:e37229.
27. Carlson J, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comarative clinical and economic outcomes of treatments for refractory non-small-cell lung cancer (NSCLC). Lung Cancer. 2008;61:405-15.
28. Fleeman N, Bagust A, McLeod C, Greenhalgh J, Boland A, Dundar Y, et al. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess. 2010;14:47-53.
29. Greenhalgh J, Mc Leod C, Bagust A, Boland A, Fleeman N, Dundar Y, et al. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess. 2010;14:47-53.